Intra-Cellular Therapies Inc (STU:23I)
€ 84.5 1 (1.2%) Market Cap: 8.97 Bil Enterprise Value: 8.06 Bil PE Ratio: 0 PB Ratio: 8.38 GF Score: 61/100

Intra-Cellular Therapies Inc LUMATEPERONE Study 403 Topline Results Transcript

Mar 28, 2023 / 12:30PM GMT
Release Date Price: €43.67 (+2.27%)
Operator

Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' conference call announcing top line results from Study 403. (Operator Instructions) As a reminder, today's conference call is being recorded. I would now like to turn the conference over to Dr. Juan Sanchez, Vice President of Corporate Communications and Investor Relations. Please go ahead.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Good morning, and thank you all for joining us on today's conference call to discuss the positive top line results from Study 403. Our press release describing the results crossed the wire earlier this morning. The slides for today's call are available on the Events and Presentations section in the Investors section of our corporate website.

Joining me on the call today are Dr. Sharon Mates, our Chairman and Chief Executive Officer; and Dr. Suresh Durgam, our Chief Medical Officer. Following the remarks, we will open the call for Q&A.

As a reminder, during today's call, we will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot